Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dose response relationship

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,391 result(s) found for: Dose response relationship. Displaying page 1 of 70.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-002342-23 Sponsor Protocol Number: 58166 Start Date*: 2016-07-29
    Sponsor Name:VU University Medical Center
    Full Title: The cardiovascular dose-response to supplemental oxygen in healthy volunteers
    Medical condition: Healthy cardiovascular system
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001856-16 Sponsor Protocol Number: 35RC17_9804_REVOLUMHOD Start Date*: 2020-09-08
    Sponsor Name:Rennes University Hospital
    Full Title: Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumor VOLUME in Patients Treated for Conventional HODgkin's Lymphoma
    Medical condition: Refractory Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-005115-29 Sponsor Protocol Number: RA1104046 Start Date*: 2005-06-24
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001509-15 Sponsor Protocol Number: 208109/231 Start Date*: 2015-06-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine (Havrix) [720 El.U/0.5 mL dose] admini...
    Medical condition: Active immunization against hepatitis A of healthy children 15 months of age at the time of the first study vaccination.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-016678-34 Sponsor Protocol Number: CRO1456 Start Date*: 2010-04-15
    Sponsor Name:Imperial College London
    Full Title: Exploring the Relationship Between Insulin Resistance and Interferon Resistance: Options to Overcome HCV Non-Response to Pegylated Interferon
    Medical condition: HCV infected patient who do not response to Pegylated Interferon. This study is trying to explore the relationship between insulin resistance and Interferon Resistance and the possible rule of Pio...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007058-79 Sponsor Protocol Number: D3190C00019 Start Date*: 2008-01-29
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Placebo-controlled, Double-blind, Parallel-group, Multicentre, Phase IIa Study to Explore the Relationship between QTcF Interval at First Dose (Loading Dose) and at Steady State after...
    Medical condition: The main purpose of this study is to investigate the feasibility to use a loading dose as a tool for identifying patients who may have an exaggerated QT response to AZD1305 and would therefore not ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002969-37 Sponsor Protocol Number: RA3103730 Start Date*: 2005-10-14
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, placebo-controlled, parallel group single dose study of GW856553 in patients with active RA to investigate the CRP dose response relationship.
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003458-42 Sponsor Protocol Number: 116938 Start Date*: 2016-06-27
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II observer-blind, multicentre, dose-ranging study of children 6 to less than 36 months of age who are to be primed with a 2-dose series of GSK Biologicals’ AS03-adjuvanted A/Indonesia/05/2...
    Medical condition: Healthy volunteers (Active immunization against influenza A virus H5N1 subtype).
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-004122-28 Sponsor Protocol Number: RR13/10782 Start Date*: 2015-03-02
    Sponsor Name:The Leeds Teaching Hospitals NHS Trust
    Full Title: An investigator‐initiated double‐blind, parallel‐group randomised controlled trial of GOLimumab and Methotrexate versus Methotrexate in very early PsA using clinical and whole body MRI outcomes: th...
    Medical condition: Adult patients with a diagnosis of Psoriatic Arthritis(PsA), (Caspar criteria) of less than 24-month duration.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-000947-26 Sponsor Protocol Number: CLFF571X2201 Start Date*: 2012-08-28
    Sponsor Name:Novartis Farmacéutica S.A
    Full Title: Multi-center, randomized, evaluator-blind, active-controlled, parallel-group design to determine safety, tolerability, and efficacy of multiple daily administration of LFF571 for 10 days in patien...
    Medical condition: Clostridium difficile infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10054236 Clostridium difficile infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001530-25 Sponsor Protocol Number: 208109/232 Start Date*: 2015-06-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine (Havrix) [720 El.U/ 0.5 mL dose] admin...
    Medical condition: Active immunization against hepatitis A, , diphtheria, tetanus, pertussis and Haemophilus influenza type B infections of healthy children 15 months of age at the time of the first study vaccination.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-006854-17 Sponsor Protocol Number: OPTIMDASATINIB 10/2008 Start Date*: 2009-03-03
    Sponsor Name:CH-Versailles
    Full Title: A PROSPECTIVE RANDOMIZED PHASE II STUDY EVALUATING THE OPTIMIZATION OF THE RESIDUAL PLASMATIC LEVEL OF DASATINIB (SPRYCEL®) IN PATIENTS NEWLY DIAGNOSED WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKA...
    Medical condition: Chronic phase chronic myelogenous leukaemia (CP-CML).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001645-41 Sponsor Protocol Number: JAK115919 Start Date*: 2013-02-19
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus.
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    16.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) EE (Completed) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-009696-34 Sponsor Protocol Number: I1F-MC-RHAK(b) Start Date*: 2009-11-23
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients with Active Rheumatoid Arthritis on Concomitant DMARD Therapy
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004293-10 Sponsor Protocol Number: IM011084 Start Date*: 2019-07-22
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects with Active Psoriatic Arthritis (PsA)
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002176-75 Sponsor Protocol Number: CZPL389A2203 Start Date*: 2019-11-05
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double blind, placebo controlled multicenter dose ranging study to assess the safety and efficacy of multiple oral ZPL389 doses in patients with moderate to severe Atopic Dermatitis (...
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) FI (Prematurely Ended) IS (Completed) AT (Prematurely Ended) EE (Prematurely Ended) BE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) FR (Prematurely Ended) ES (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000442-39 Sponsor Protocol Number: 106962 Start Date*: 2006-04-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, phase I/II study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ 11PCV combined with adjuvant AS02V given as a 2-dose vaccination in adults aged 18-40 years old.
    Medical condition: Two doses vaccination in adults subjects aged between 18 and 40 years old, in good general health and not previously immunized with the 23-valent pneumococcal polysaccharide vaccine.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002116-14 Sponsor Protocol Number: CCTL019G2201J Start Date*: 2018-10-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive...
    Medical condition: Pediatric and young adult patients aged 1 to 25 years with first-line NCI high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL) who are in CR1 with minimal residual disease (MRD) positive (MR...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    21.0 100000004864 10063621 Acute lymphoblastic leukaemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Temporarily Halted) DK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) NL (Trial now transitioned) NO (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000164-24 Sponsor Protocol Number: 109836 Start Date*: 2007-05-21
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I/II, partially-blind, randomized multicentre study to assess the safety and immunogenicity of an HPV-16/18/33/58 L1 VLP vaccine formulated with different adjuvant systems when administered...
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003258-21 Sponsor Protocol Number: PDC-01-0205 Start Date*: 2022-05-19
    Sponsor Name:Cessatech A/S
    Full Title: Analgesic Efficacy and Pharmacokinetic-pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 after Impacted Mandibular Third Molar Extraction
    Medical condition: Healthy male or female participants scheduled for surgical removal of an impacted mandibular third molar, where bone removal is judged to be needed.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004865 10050327 Dental surgery NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 12:02:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA